Display options
Cite
Jach R, Basta A, Kotarski J, et al. Ten years of anti-HPV vaccinations: what do we know?. Prz Menopauzalny. 2016;15(3):170-175doi: 10.5114/pm.2016.63497.
Jach, R., Basta, A., Kotarski, J., Markowska, J., Paszkowski, T., Dębski, R., Rokita, W., Kędzia, W., & Kiszka, K. (2016). Ten years of anti-HPV vaccinations: what do we know?. Przeglad menopauzalny = Menopause review, 15(3), 170-175. https://doi.org/10.5114/pm.2016.63497
Jach, Robert, et al. "Ten years of anti-HPV vaccinations: what do we know?." Przeglad menopauzalny = Menopause review vol. 15,3 (2016): 170-175. doi: https://doi.org/10.5114/pm.2016.63497
Jach R, Basta A, Kotarski J, Markowska J, Paszkowski T, Dębski R, Rokita W, Kędzia W, Kiszka K. Ten years of anti-HPV vaccinations: what do we know?. Prz Menopauzalny. 2016 Nov;15(3):170-175. doi: 10.5114/pm.2016.63497. Epub 2016 Nov 15. PMID: 27980529; PMCID: PMC5137481.
Copy Download .nbib Format: NLM
Share it on

Prz Menopauzalny. 2016 Nov;15(3):170-175. doi: 10.5114/pm.2016.63497. Epub 2016 Nov 15.

Ten years of anti-HPV vaccinations: what do we know?.

Przeglad menopauzalny = Menopause review

Robert Jach, Antoni Basta, Jan Kotarski, Janina Markowska, Tomasz Paszkowski, Romuald Dębski, Wojciech Rokita, Witold Kędzia, Krystyna Kiszka

Affiliations

  1. Clinic of Endocrynologic Gynecology, University Hospital UJ CM, Krakow, Poland.
  2. Clinic of Gynecologic Oncology, University Hospital UJ CM, Krakow, Poland.
  3. First Clinic of Gynecologic Oncology and Gynecology, Medical University of Lublin, Lublin, Poland.
  4. Clinic of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
  5. III Chair and Clinic of Gynecology, Medical University of Lublin, Lublin, Poland.
  6. Department of Gynecology and Obstetrics CMKP, Biela?ski Hospital, Warsaw, Poland.
  7. Clinic of Gynecology and Obstetrics, WSZ, Kielce, Poland.
  8. Clinic of Gynecology, Gynecologic-Obstetrical Clinical Hospital UM in Poznan, Poland.
  9. Department of Gynecology and Obstetrics SP ZOZ in My?lenice, Poland.

PMID: 27980529 PMCID: PMC5137481 DOI: 10.5114/pm.2016.63497

Abstract

Human papillomavirus (HPV) is one of the most important carcinogens in humans. Vaccines against HPV are now considered the first anti-cancer vaccinations. Since 2007, in many developed countries, there have been recommendations present for preventive vaccines against HPV. At present, the degree of implementation of these recommendations depends on a number of country-specific factors such as the health care system organization or the ways of funding. HPV vaccines are primarily to prevent the development of cervical cancer and other genital cancers. Therefore, only their long-term effectiveness can be measured, when a correspondingly large cohort of vaccinated teenagers reaches the age of the greatest incidence of these cancers. However, great care should be taken in assessing the results of vaccinations due to the possibility of misinterpretation and possible erroneous data. Undoubtedly, teenagers are the target population of HPV vaccines. However, vaccinating young sexually active women is also justified from an individual point of view. A 9-valent vaccine has been registered in the USA and in Europe - including Poland - as one of the three preventive vaccines. It is recommended to vaccinate women between 13 and 26 and men between 13 and 21, previously unvaccinated. It is also recommended to vaccinate men aged 26 years or less who have sexual relations with other men and people with reduced immunity, including HIV-positive people who have not been vaccinated previously.

Keywords: HPV; HPV vaccine; human papillomavirus

References

  1. Lancet Oncol. 2012 Jun;13(6):607-15 - PubMed
  2. N Engl J Med. 2015 Feb 19;372(8):711-23 - PubMed
  3. BMJ. 2013 Apr 18;346:f2032 - PubMed
  4. Lancet Oncol. 2010 Nov;11(11):1048-56 - PubMed
  5. Vaccine. 2014 May 30;32(26):3237-42 - PubMed
  6. Lancet. 2011 Jun 18;377(9783):2085-92 - PubMed
  7. N Engl J Med. 2007 May 10;356(19):1928-43 - PubMed
  8. Epidemiol Rev. 2006;28:88-100 - PubMed
  9. Expert Rev Anti Infect Ther. 2011 Aug;9(8):627-39 - PubMed
  10. Lancet Oncol. 2015 Jul;16(7):739-40 - PubMed
  11. J Infect Dis. 2012 Dec 1;206(11):1645-51 - PubMed
  12. JAMA. 2013 May 1;309(17):1793-802 - PubMed
  13. Hum Vaccin Immunother. 2014;10(5):1155-65 - PubMed
  14. Int J Cancer. 2003 Oct 10;106(6):896-904 - PubMed
  15. Hum Vaccin. 2011 Dec;7(12):1374-86 - PubMed
  16. Sex Transm Dis. 2013 Feb;40(2):130-5 - PubMed
  17. Lancet Oncol. 2012 Jan;13(1):89-99 - PubMed
  18. J Low Genit Tract Dis. 2012 Jul;16(3):175-204 - PubMed
  19. N Engl J Med. 2011 Oct 27;365(17):1576-85 - PubMed
  20. J Infect Dis. 2013 Aug 1;208(3):385-93 - PubMed
  21. Vaccine. 2007 Jun 21;25(26):4931-9 - PubMed
  22. MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30 - PubMed
  23. Pediatrics. 2012 Nov;130(5):798-805 - PubMed
  24. Lancet. 2009 Jul 25;374(9686):301-14 - PubMed
  25. N Engl J Med. 2011 Feb 3;364(5):401-11 - PubMed
  26. Sex Health. 2011 Jun;8(2):171-8 - PubMed
  27. J Adolesc Health. 2013 Dec;53(6):679-82 - PubMed
  28. Lancet. 2009 Jun 6;373(9679):1949-57 - PubMed

Publication Types